Healthcare Payments Automation at a Discount to Intrinsic Value

Waystar Holding Corp. (NASDAQ: WAY) is a healthcare payments and revenue cycle management software company. The company provides cloud-based software that automates the financial side of healthcare delivery — from the moment a patient schedules an appointment through final payment collection.

How the company makes money: Waystar generates revenue primarily through recurring subscription and transaction-based fees tied to the volume of claims and payments processed on its platform. Because revenue scales with provider activity rather than one-time license sales, the model is highly recurring and predictable. The company serves a broad customer base spanning large hospital systems, ambulatory surgery centers, physician practices, and clinics.

Customers and scale: Waystar's platform is used by a substantial share of U.S. hospitals and a large number of physician groups, giving it network effects: as more providers and payers transact on the platform, the data set improves, which improves automation accuracy, which improves outcomes for customers. With a $5.0B market cap and 191.75M shares outstanding, Waystar is a mid-cap healthcare IT company with the scale to invest in AI and the focus to compete effectively against both point solutions and larger horizontal players.

Ownership structure: The 139.35M public float against 191.75M shares outstanding implies roughly 52.4M shares remain closely held — a legacy of the company's private-equity ownership history. This concentration can amplify volatility but also aligns long-term holders with management.

Near-term drivers (next 12–24 months):

• Pricing and cross-sell: Waystar has a large installed base with room to attach additional modules — denial management, patient payments, coding automation — driving net revenue retention higher.
• AI monetization: New AI-powered features for claims scrubbing and denial prediction can be sold as premium add-ons, lifting average revenue per customer.
• Deleveraging: Free cash flow directed at debt reduction lowers interest expense and improves earnings per share, a mechanical tailwind given the company's post-IPO capital structure.

Medium-term drivers (3–5 years):

• Market share gains in ambulatory and specialty segments: Waystar can extend beyond its hospital stronghold into faster-growing outpatient settings.
• Payer-side expansion: Deeper connectivity with payers enables real-time eligibility and prior authorization, expanding the addressable spend per transaction.
• International and adjacent verticals: Longer-dated optionality, though we do not underwrite significant contribution in our base case.

We model revenue growth in the high-single to low-double-digit range annually, with adjusted EBITDA margins expanding several hundred basis points over the forecast period as automation and scale take hold.

What's driving these trends: Revenue growth is moderating from the low-teens into the high-single digits as the company laps pricing actions, but the mix is improving — more recurring subscription revenue, more AI attach, and higher retention. Gross margin expansion reflects the shift toward software-delivered automation and away from labor-heavy services. The most important line is free cash flow: growing from roughly $180M to nearly $385M over the forecast period, which funds debt reduction and, eventually, opportunistic capital return. Reported EPS of $0.70 (trailing) understates adjusted earnings power because of amortization and stock-based compensation tied to the IPO and sponsor era.

Market size: U.S. healthcare revenue cycle management is a large market — we estimate the addressable opportunity for software-led RCM at $15–20B annually and growing at a high-single-digit rate, driven by rising claim volumes, growing patient financial responsibility, and payer-provider friction that increases denial rates.

Competitive positioning: Waystar's key advantage is scale and breadth. It competes against:

• Change Healthcare (UnitedHealth Group / Optum): The largest competitor by volume, but its 2024 cyberattack disrupted the market and created a multi-year opening for competitors to win share. Regulatory scrutiny of UnitedHealth's vertical integration is an additional tailwind for Waystar.
• Evolent Health (EVH): Focused more on specialty care management and payer-provider performance; overlaps with Waystar at the margins but is not a direct substitute in core claims processing.
• R1 RCM (acquired by TowerBrook/CD&R in 2024): A technology-enabled RCM services provider that competes for large hospital system contracts, often bundling services with software.
• Oracle Health (Cerner) and Epic: EHR vendors that offer native RCM modules. Their strength is integration; Waystar's counter is best-of-breed functionality and payer connectivity.

Waystar's positioning is strongest in the mid-market and with providers who want a dedicated RCM partner rather than a module bolted onto an EHR. The Change Healthcare disruption remains a live share-gain opportunity through 2026.

DCF discussion: We model a 10-year explicit forecast with revenue growing from roughly $960M in FY2025E to approximately $1.9B by FY2034E, adjusted EBITDA margins expanding from 36.5% to 42%, and capital expenditures and working capital requirements consistent with a capital-light software model. Using a weighted average cost of capital of 8.5% — justified by the company's low beta of 0.15, modest leverage, and recurring revenue — and a terminal growth rate of 3.0%, we derive an enterprise value that supports an equity value of approximately $33 per share. Sensitivity to a 100bp change in WACC moves the fair value by roughly $4–5 per share.

Comparable-company analysis:

Waystar trades at a premium to smaller, slower-growing peers but at a discount to where R1 RCM was taken private and to the broader healthcare IT group on a growth-adjusted basis. Blending our DCF ($33) with a comparable-company multiple of roughly 5.5x NTM revenue and 15x NTM EBITDA ($32–34), we arrive at a 12-month price target of $33.00.

• Customer concentration and hospital budget cycles: A meaningful share of revenue comes from large health systems. If hospital capital budgets tighten or consolidation slows, contract wins and expansions could be delayed.
• Competition from EHR vendors and Optum: Epic and Oracle Health continue to improve native RCM offerings, and UnitedHealth's Optum remains a formidable competitor despite the Change Healthcare disruption. A sustained competitive response could pressure pricing and retention.
• Regulatory and reimbursement risk: Changes to healthcare reimbursement rules, prior authorization requirements, or data privacy regulation (HIPAA, state-level rules) could raise compliance costs or alter customer economics.
• Leverage and interest rate exposure: Waystar carries debt from its sponsor era. While free cash flow is strong, a rising rate environment or a slowdown in cash generation could strain the balance sheet and limit strategic flexibility.
• Short interest and volatility: With 8.46% of the float short and a public float of 139.35M shares, the stock is prone to sharp moves in both directions around earnings and guidance. The 52-week range of $17.26–$40.35 illustrates this volatility.